A Single-center, Randomized, Investigator/Subject-Blind, Adaptive Single-ascending Dose (Part 1) and Multiple Ascending Dose (Part 2), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6889450 Following Oral Administration in Healthy Subjects

Trial Profile

A Single-center, Randomized, Investigator/Subject-Blind, Adaptive Single-ascending Dose (Part 1) and Multiple Ascending Dose (Part 2), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6889450 Following Oral Administration in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs RO 6889450 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 01 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
    • 01 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
    • 02 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top